Welcome to ECMTF
The European CMT Federation has been created to unite all the CMT organisations across Europe to help promote better care for people with Charcot-Marie-Tooth disease, fund research and encourage the formation of new organisations in countries where there isn't one at present.
The French company Pharnext, CMT scientific experts, and international patient advocacy organizations (PAOs) have partnered to study the impact of CMT on patients’ daily lives. The result of that partnership is the CMT&Me study, which Pharnext is sponsoring over two years in six countries: the US, UK, Germany, France, Italy and Spain. The aim of the study is to collect real time data directly from patients, who describe what it is like to live with CMT. The study also aims to find out how treatment can improve patient quality of life and slow CMT progression. Pharnext hopes this information will help researchers develop better treatments for CMT.
To learn more, visit the Vitaccess website.
Do you have CMT?
We encourage people with CMT across Europe to contact the Member organisations for support. If there is not one in your country, they may be able to answer your questions but are unlikely to be able to do so in your language.
Please check here to see if there is a group in your country.
What is CMT?
CMT - or Charcot-Marie-Tooth disease is a rare neurological condition affecting the nerves to the arms and legs. The nerves deteriorate causing muscle wasting and weakness to the lower legs/feet and lower arms/hands, mainly, leading to varying degrees of disablity, with balance, walking, standing, using the hands/fingers all becoming a problem. The condition is hereditary, and slowly progressive, but is usually not life-threatening.